A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

M Gnant; G Steger; Richard Greil; F Fitzal; Brigitte Mlineritsch; D Manfreda; C Tausch; M Balic; P Dubsky; Martin Moik; J Thaler; D Egle; V Bjelic-Radisic; U Selim; R Exner; C Singer; E Melbinger-Zeinitzer; F Haslbauer; H Stoger; R Helfgott; P Sevelda; H Trapl; V Wette; L Solkner; R Jakesz

A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

M Gnant, G Steger, Richard Greil, F Fitzal, Brigitte Mlineritsch, D Manfreda, C Tausch, M Balic, P Dubsky, Martin Moik, J Thaler, D Egle, V Bjelic-Radisic, U Selim, R Exner, C Singer, E Melbinger-Zeinitzer, F Haslbauer, H Stoger, R HelfgottP Sevelda, H Trapl, V Wette, L Solkner, R Jakesz

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

19 Citations (Web of Science)

Original language	English
Journal	CANCER RESEARCH
Volume	78
Issue number	4
Publication status	Published - 2018
Event	San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 5 Dec 2017 → 9 Dec 2017

Cite this

Gnant, M., Steger, G., Greil, R., Fitzal, F., Mlineritsch, B., Manfreda, D., Tausch, C., Balic, M., Dubsky, P., Moik, M., Thaler, J., Egle, D., Bjelic-Radisic, V., Selim, U., Exner, R., Singer, C., Melbinger-Zeinitzer, E., Haslbauer, F., Stoger, H., ... Jakesz, R. (2018). A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial. CANCER RESEARCH , 78(4).

Gnant, M ; Steger, G ; Greil, Richard et al. / A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial. In: CANCER RESEARCH 2018 ; Vol. 78, No. 4.

@article{cb2c56cdf11c43d0a33c856ccefa4aab,

title = "A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial",

author = "M Gnant and G Steger and Richard Greil and F Fitzal and Brigitte Mlineritsch and D Manfreda and C Tausch and M Balic and P Dubsky and Martin Moik and J Thaler and D Egle and V Bjelic-Radisic and U Selim and R Exner and C Singer and E Melbinger-Zeinitzer and F Haslbauer and H Stoger and R Helfgott and P Sevelda and H Trapl and V Wette and L Solkner and R Jakesz",

year = "2018",

language = "English",

volume = "78",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "4",

note = "San Antonio Breast Cancer Symposium ; Conference date: 05-12-2017 Through 09-12-2017",

}

Gnant, M, Steger, G, Greil, R, Fitzal, F, Mlineritsch, B, Manfreda, D, Tausch, C, Balic, M, Dubsky, P, Moik, M, Thaler, J, Egle, D, Bjelic-Radisic, V, Selim, U, Exner, R, Singer, C, Melbinger-Zeinitzer, E, Haslbauer, F, Stoger, H, Helfgott, R, Sevelda, P, Trapl, H, Wette, V, Solkner, L & Jakesz, R 2018, 'A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial', CANCER RESEARCH , vol. 78, no. 4.

A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial. / Gnant, M; Steger, G; Greil, Richard et al.
In: CANCER RESEARCH , Vol. 78, No. 4, 2018.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

AU - Gnant, M

AU - Steger, G

AU - Greil, Richard

AU - Fitzal, F

AU - Mlineritsch, Brigitte

AU - Manfreda, D

AU - Tausch, C

AU - Balic, M

AU - Dubsky, P

AU - Moik, Martin

AU - Thaler, J

AU - Egle, D

AU - Bjelic-Radisic, V

AU - Selim, U

AU - Exner, R

AU - Singer, C

AU - Melbinger-Zeinitzer, E

AU - Haslbauer, F

AU - Stoger, H

AU - Helfgott, R

AU - Sevelda, P

AU - Trapl, H

AU - Wette, V

AU - Solkner, L

AU - Jakesz, R

PY - 2018

Y1 - 2018

M3 - Abstract (Journal)

SN - 0008-5472

VL - 78

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 4

T2 - San Antonio Breast Cancer Symposium

Y2 - 5 December 2017 through 9 December 2017

ER -

Gnant M, Steger G, Greil R, Fitzal F, Mlineritsch B, Manfreda D et al. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial. CANCER RESEARCH . 2018;78(4).